Marco Metra to Atrial Fibrillation
This is a "connection" page, showing publications Marco Metra has written about Atrial Fibrillation.
Connection Strength
1.290
-
Implications of atrial fibrillation on the clinical course and outcomes of hospitalized COVID-19 patients: results of the Cardio-COVID-Italy multicentre study. Europace. 2021 10 09; 23(10):1603-1611.
Score: 0.326
-
Atrial fibrillation in the COVID-19 era: simple bystander or marker of increased risk? Eur Heart J. 2020 07 01; 41(32):3094.
Score: 0.298
-
GENETIC-AF: Digging Deeper Into Genotype-Phenotype and Heart Failure-Atrial Fibrillation Interactions. JACC Heart Fail. 2019 07; 7(7):599-601.
Score: 0.278
-
Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy. Eur Heart J. 2020 05 14; 41(19):1821-1829.
Score: 0.074
-
April 2019 at a glance: prediction of heart failure, left atrial function, cardio-oncology. Eur J Heart Fail. 2019 04; 21(4):393-394.
Score: 0.068
-
Dose-dependent efficacy of ß-blocker in patients with chronic heart failure and atrial fibrillation. Int J Cardiol. 2018 Dec 15; 273:141-146.
Score: 0.065
-
Prognostic evaluation of the elastic properties of the ascending aorta in dilated cardiomyopathy. Eur J Clin Invest. 2018 Jul; 48(7):e12950.
Score: 0.064
-
Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial. Clin Res Cardiol. 2017 Jun; 106(6):444-456.
Score: 0.059
-
Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48. Eur J Heart Fail. 2016 09; 18(9):1153-61.
Score: 0.056